W

Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871

Watchlist Manager
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Watchlist
Price: 11.71 CNY -0.26% Market Closed
Market Cap: 1.9B CNY
Have any thoughts about
Wuhan Hvsen Biotechnology Co Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-1 449
Current
39.5
Median
13.5
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1 449
=
Enterprise Value
2.4B CNY
/
EBITDA
-1.6m CNY
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
CN
W
Wuhan Hvsen Biotechnology Co Ltd
SZSE:300871
Average EV/EBITDA: 459.2
Negative Multiple: -1 449
4 181%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
6.3
2-Years Forward
EV/EBITDA
4.8
3-Years Forward
EV/EBITDA
4.1

See Also

Discover More